Ipsit Pharmaceuticals Private Limited
About Ipsit Pharmaceuticals Private Limited
Data last updated:
Ipsit Pharmaceuticals Private Limited is a private limited company based in Mehsana, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 19 August 2021 and has been in existence for over 5 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN U24200GJ2021PTC125006.
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Alpesh Kumar Mulchandbhai Patel and Mittal Alpeshbhai Patel.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Block No.93 Nr. Jalaram Temple At – Palavasana Ta – Mehsana, Gujarat, India – 384003.
As per the financials filed for FY 2024, the company reported a revenue of ₹43.64 Lakh, a growth of 36% compared to the previous year. For the same year it recorded a net profit of ₹8.03 Lakh (net margin 18.4%) and EBITDA of ₹11.27 Lakh (EBITDA margin 25.8%).
Company details
Contact details
Ipsit Pharmaceuticals Private Limited's registered office is in Mehsana, Gujarat.
- Registered AddressBlock No.93 Nr. Jalaram Temple At – Palavasana Ta – Mehsana, Gujarat, India – 384003
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Ipsit Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Ipsit Pharmaceuticals Private Limited, buy the company report.
Financials of Ipsit Pharmaceuticals Private Limited
FY 2025 filings availableIpsit Pharmaceuticals Private Limited reported revenue of ₹43.64 Lakh (up 36% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue rose 36% in the latest year. EBITDA rose 117% in the latest year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|
| Profit and Loss Statement | |||
| Revenue from Operations | |||
| Other Income | |||
| Total Revenue | |||
| Cost of Materials Consumed | |||
| Employee Benefit Expense | |||
| Finance Costs | |||
| Depreciation and Amortisation | |||
| Other Expenses | |||
| Total Expenses | |||
| EBITDA | ₹11.27 Lakh | ||
| Profit Before Tax | |||
| Tax Expense | |||
| Net Profit (PAT) | ₹8.03 Lakh | ||
| Balance Sheet | |||
| Share Capital | |||
| Reserves and Surplus | |||
| Net Worth (Total Equity) | |||
| Long-term Borrowings | |||
| Short-term Borrowings | |||
| Trade Payables | |||
| Total Liabilities | |||
| Fixed Assets | |||
| Investments | |||
| Inventories | |||
| Trade Receivables | |||
| Cash and Bank Balance | |||
| Total Assets | |||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|
| Profitability | |||
| EBITDA Margin | 25.8% | ||
| Net Profit Margin | 18.4% | ||
| Return on Equity (ROE) | |||
| Return on Capital Employed (ROCE) | |||
| Return on Assets (ROA) | |||
| Liquidity and Debt | |||
| Current Ratio | |||
| Quick Ratio | |||
| Debt-to-Equity Ratio | |||
| Interest Coverage Ratio | |||
| Efficiency and Growth | |||
| Asset Turnover | |||
| Receivable Days | |||
| Payable Days | |||
| Inventory Days | |||
| Revenue Growth | |||
| Net Profit Growth | |||
To see the full financial statements and ratios of Ipsit Pharmaceuticals Private Limited, buy the company report.
Board of directors of Ipsit Pharmaceuticals Private Limited
Ipsit Pharmaceuticals has 2 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Alpesh Kumar Mulchandbhai Patel | Director | 19 Aug 2021 | 5 Years 2 Months | Current |
| Mittal Alpeshbhai Patel | Director | 26 Aug 2022 | 4 Years 2 Months | Current |
Peer comparison
Ipsit Pharmaceuticals Private Limited is compared with the 3 companies closest to it by revenue in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Almighty Pharmaceuticals Private Limited | ₹43.92 Lakh (FY 2025) | 8.0% | Jhunjhunu, Rajasthan, India | |||
| Avius Pharmaceuticals Private Limited | ₹43.83 Lakh (FY 2025) | 21.0% | Ludhiana, Punjab, India | |||
| Ipsit Pharmaceuticals Private Limitedthis company | ₹43.64 Lakh (FY 2024) | ₹8.03 Lakh | 18.4% | 36.0% | Mehsana, Gujarat, India | |
| Induct Pharmaceuticals Private Limited | ₹43.2 Lakh (FY 2025) | -17.0% | Surat, Gujarat, India |
To see the full peer comparison of Ipsit Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Ipsit Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Ipsit Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Ipsit Pharmaceuticals Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Ipsit Pharmaceuticals Private Limited has 4 board changes on record since 2021: 2 appointments and 2 cessations. The latest: Mittal Alpeshbhai Patel ceased to be Additional Director on 10 Mar 2023.
Frequently asked questions
Ipsit Pharmaceuticals is an active private limited company based in Mehsana, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 19 August 2021 (5+ years old) and is registered under CIN U24200GJ2021PTC125006.
Ipsit Pharmaceuticals has 2 current directors:
- Alpesh Kumar Mulchandbhai Patel - Director
- Mittal Alpeshbhai Patel - Director
The latest financial statements of Ipsit Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2022 are in the company report.
The CIN (Corporate Identification Number) of Ipsit Pharmaceuticals is U24200GJ2021PTC125006. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Ipsit Pharmaceuticals was incorporated on 19 August 2021, making it 5+ years old. It is registered with the Registrar of Companies, Ahmedabad.
The peers of Ipsit Pharmaceuticals by revenue are Almighty Pharmaceuticals Private Limited, Avius Pharmaceuticals Private Limited, Induct Pharmaceuticals Private Limited, all in the Pharma industry (Pharmaceuticals), with the same principal business activity (wholesale trading).
Mittal Alpeshbhai Patel ceased to be Additional Director on 10 Mar 2023. Nehalkumar Sureshchandra Patel ceased to be Director on 05 Sep 2022. Mittal Alpeshbhai Patel was appointed as Director on 26 Aug 2022. Ipsit Pharmaceuticals has 4 board changes on record in total.
The registered office of Ipsit Pharmaceuticals is at Block No.93 Nr. Jalaram Temple At – Palavasana Ta – Mehsana, Gujarat, India – 384003.
Ipsit Pharmaceuticals operates in the pharma industry, in the drug formulation and development segment.
Ipsit Pharmaceuticals can be reached at its registered office: Block No.93 Nr. Jalaram Temple At – Palavasana Ta – Mehsana, Gujarat, India – 384003.
Ipsit Pharmaceuticals is registered under the jurisdiction of the Registrar of Companies (ROC), Ahmedabad.